Novaliq today launched its dry eye disease therapy, NovaTears, in New Zealand and said that it won registrational approval in Australia. The Germany-based company inked an exclusive licensing partnership earlier this year with AFT Pharmaceuticals (ASX:AFP) to commercialize Novaliq’s water-free topical eye drops in Australia. Get the full story at our sister site, Drug Delivery Business News.
AFT Pharmaceuticals
Novaliq, AFT Pharmaceuticals ink licensing deal for NovaTears dry eye therapy
Ocular therapeutics company Novaliq said today that it inked a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of its dry eye therapy, NovaTears, in Australia and New Zealand. NovaTears is the Germany-based company’s 1st commercially available product indicated for the treatment of evaporative dry eye diseases. Get the full story at our sister site, Drug […]